Mannisol A (Mannitol)

Mannitol works by creating an osmotic gradient that pulls water from cells and interstitial spaces into the bloodstream. This expands plasma volume, enhances renal filtration, promotes diuresis, and reduces cerebral edema by decreasing brain water content.

The dose of Mannisol A is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Dosage regimens are individualized and should follow the prescriber’s instructions and local guidelines.

Safety data for Mannisol A in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Mannisol A, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mannisol A (mannitol) is a classic osmotic diuretic with a rapid onset of action and a well‑established safety profile. Compared with hypertonic saline, mannitol provides a more predictable osmotic effect and is preferred for acute reduction of intracranial pressure and renal protection in many clinical protocols.

Mannisol A should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for administration.

Mannisol A is administered intravenously by slow infusion, typically through a peripheral or central line. The infusion rate and total volume are set by the prescriber, and the solution should be administered using aseptic technique to avoid contamination.

Serious risks include pulmonary edema, severe dehydration, anaphylactic reactions, worsening renal failure, and cardiac arrhythmias due to electrolyte disturbances. Prompt recognition of these events and immediate medical intervention are essential.

Mannisol A is contraindicated in patients with known hypersensitivity to mannitol, severe renal impairment where diuresis is ineffective, active pulmonary edema, and in those with uncontrolled heart failure where fluid shifts could worsen the condition.